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Purpose: Current guidelines propose the use of low doses of antipsychotics in the treatment of first-episode psychosis 
(FEP) patients.  This study aims to examine the pattern of antipsychotic use in the first months of psychosis in a sample of 
Portuguese patients. 
 
Materials and Methods: Electronic medical records were retrospectively analyzed and antipsychotic treatment was 
evaluated during initial weeks (baseline) of treatment and current time (follow-up).  
 
 
Table 1. Sample Characteristics 
N 
Male n (%) 
Age years mean (SD) 
Civil status 
Single 
Married 
Divorced/separated 
 
Employment 
Employed 
Unemployed 
Student 
 
DUP days n (SD) 
 
Diagnosis 
Schizophrenia 
Psychosis NOS 
Cannabis induced Psychotic Disorder 
Delusional disorder 
Psychotic depression 
Bipolar disorder, manic episode 
 
Cannabis use n (%) 
40 
24 (60%) 
29.7 (8.4) 
 
27 
7 
6 
 
 
11 
22 
7 
 
470.6 (693.3) 
 
 
11 
18 
7 
2 
1 
1 
 
20 (50%) 
Conclusion: Our results are in line with current guidelines regarding FEP. Our sample of FEP patients were mainly treated 
with atypical antipsychotics. Clozapine was only used as alternative antipsychotic when two others were not effective. 
Injectable long acting antipsychotics were used in a significant proportion of the patients.  
 
Results: The sample includes 40 consecutive affective and non-affective FEP 
patients, with a mean time of follow-up of 16.2 months (SD: 10.3). The mean age of 
the sample was 29.7 years, 60% males, with a duration of untreated psychosis (DUP) 
of 470.6 days (SD: 693.3). At baseline, 37 (92.5%) of the patients were treated with 
atypical antipsychotics. Twelve (30%) patients were initially treated with risperidone, 
8 (20%) with olanzapine, 5 (12.5%) with aripiprazole, 3 (7.5%) with paliperidone and 
2 (5%) with haloperidol. Of the 40 patients, 22 (55%) continued the initially 
prescribed antipsychotic at follow-up assessment, 16 (40%) switched to an 
alternative antipsychotic and 2 (5%) were lost to follow-up. At follow-up, 9 (22.5%) 
patients were taking risperidone, 6 (15%) patients aripiprazole, 3 (7.5%) patients 
paliperidone, 2 (5%) patients olanzapine, 2 (5%) patients clozapine, 1 (2.6%) patient 
sustained-released quetiapine, 1 (2.6%) patient amissulpride and 1 (2.6%) patient 
haloperidol. Injectable long acting antipsychotics were used in 22.5% of patients at 
baseline and in 32.5% at follow-up. 
 
Table 2. Baseline antipsychotic prescription 
Typical antipsychotic (oral) 
Haloperidol 
 
Atypical antipsychotics (oral) 
Risperidone 
Olanzapine 
Aripiprazole 
Paliperidone 
Quetiapine SR 
 
Injectable long-acting 
antipsychotics 
Paliperidone LAI 
Zuclopenthixol decanoate 
Risperidone LAI 
 
2 (5%) 
 
 
12 (30%) 
8 (20%) 
5 (12.5%) 
3 (7.5%) 
1 (2.5%) 
 
 
 
7 (17.5%) 
1 (2.5%) 
1 (2.5%) 
 
Table 3. Follow-up antipsychotic prescription 
Mean time follow-up Mean (SD) months 
 
Typical antipsychotic (oral) 
Haloperidol 
 
Atypical antipsychotics (oral) 
Risperidone 
Aripiprazole 
Paliperidone 
Olanzapine 
Quetiapine SR 
Amissulpride 
Clozapine 
 
Injectable long-acting antipsychotics 
Paliperidone LAI 
Haloperidol decanoate 
Risperidone LAI 
Zuclopenthixol decanoate 
 
Lost follow-up 
 
Continued initially prescribed antipsychotic 
 
Switched to an alternative antipsychotic 
16.2 (SD: 10.3) 
 
 
1 (2.63%) 
 
 
9 (22.5%) 
6 (15%) 
3 (7.5%) 
2 (5%) 
1 (2.6%) 
1 (2,6%) 
2 (5.2%) 
 
 
9 (22.5%) 
2 (5.2%) 
1 (2.6%) 
1 (2.6%)  
 
2 (5%) 
 
22 (55%) 
 
16 (40%) 
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